Reporting from: – 40th Annual Meeting of the American Society of Clinical Oncology, New Orleans, June 5-8, 2004 – New England Journal of Medicine In this edition: At the ASCO conference Ga
Reporting from:
– 40th Annual Meeting of the American Society of Clinical Oncology, New Orleans, June 5-8, 2004
– New England Journal of Medicine
In this edition:
At the ASCO conference Gary Strauss discussed his results with adjuvant therapy for early non-small cell lung cancer which show improved survival rates. Similarly, results from Timothy Winton’s team point to the addition of chemotherapy, a view endorsed by Bruce Johnson, Aman Buzdar’s group has shown a clear advantage from using chemotherapy including trastuzumab before operating on breast cancer patients. Harold Burstein discussed the liklihood that in patients with HER/2 positive disease trastuzumab-containing neoadjuvant regimens may become standard.
Tim Oliver, described how single-shot carboplatin therapy may be just as effective at removing the risk of further testicular cancer after surgery as radiotherapy, but without collateral iatrogenic cancer risk.
Frances Shepherd, talked about her findings with the targeted agent erlotinib in a phase III trial among patients with advanced non-small cell lung cancer patients who did not respond to standard therapy. Kathy Albain, commented on the clinical implications.
…
Related Episodes
David R Spigel MD; ASCO 2026: Bispecific PD-1/VEGF Antibody Ivonescimab Extends Life in Patients with Untreated Advanced Non–Small Cell Lung Cancer: Phase 3 HARMONi-6 trial
CHICAGO, USA—The bispecific antibody ivonescimab (that targets the PD-1 and VEGF molecules) has extended overall survival in patients with untreated advanced squamous non-small cell lung cancer in the latest data from the HARMONi-6 trial reported at the 2026 Annual Meeting of the American Society of Clinical Oncology by Chen Zhiwei from Jiao Tong University in Shanghai, China. Peter Goodwin discusses the findings with ASCO expert David R Spigel MD, President & Chief Medical Officer at the Sarah Cannon Research Institute in Nashville, Tennessee, USA
Vanita Noronha MD; ASCO 2026: Ultra-Low Dose Immunotherapy Extends Life with Metastatic Head and Neck Cancer at Low Cost for Patients in Low and Middle Income Countries
CHICAGO, USA—Although recurrent or metastatic head and neck cancers respond well to palliative chemotherapy with immune checkpoint inhibition, this approach may be un-affordable in low and middle income countries. But a randomized phase three trial from India reported a pragmatic solution at the 2026 Annual Meeting of the American Society of Clinical Oncology. Ultra-low doses of pembrolizumab immunotherapy along with “triple oral metronomic chemotherapy” were found to bring good palliation and longer survival according to Vanita Noronha MD, Professor of Medical Oncology, Tata Memorial Hospital, Mumbai, India, as she explained to Peter Goodwin.
John Mascarenhas MD; ASCO 2026: New Janus Kinase Inhibitor Improves Myelofibrosis Outcomes When Added to Ruxolitinib Initial Therapy
CHICAGO, USA—Outcomes were improved for patients with myelofibrosis in the phase 3 SENTRY trial who were randomized to have the new Janus kinase inhibitor selinexor added to their ruxolitinib initial therapy.Findings were reported at the 2026 Annual Meeting of the American Society of Clinical Oncology.Peter Goodwin got the details from first author John Mascarenhas MD, Professor of Medicine and Director of the Center of Excellence for Blood Cancers and Myeloid Disorders at the Tisch Cancer Institute, Icahn School of Medicine, in Mount Sinai, New York, NY.